ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Valuation Check After BiPASS Phase 3 Trial Reaches First U.S. Patient
Telix Pharmaceuticals (ASX:TLX) has dosed the first U.S. patient in its BiPASS Phase 3 trial, which is testing Illuccix and Gozellix alongside MRI in initial prostate cancer diagnosis, with the goal of refining biopsy decisions.
See our latest analysis for Telix Pharmaceuticals.
The BiPASS milestone lands at a time when Telix’s 1 day share price return of 2.96% and 7 day share price return of 2.14% sit against a 90 day share price decline of 31.05%. The 1 year total shareholder return decline...